Real-life practice: adherence and discontinuation of Rybelsus therapy

by

Rybelsus in the Real World: Why Adherence Matters

Rybelsus (oral semaglutide) has marked a new chapter in type 2 diabetes management. As the first and only GLP-1 receptor agonist available in pill form, it offers a needle-free alternative to injectable medications like Ozempic or Trulicity-making it especially attractive to patients who are reluctant to start injections.

Learn more about how Rybelsus works →
here

But when it comes to real-world outcomes, convenience is only one part of the equation. The clinical efficacy seen in trials depends heavily on how consistently patients take the medication over time. That’s where real-world adherence and persistence come into focus.

In this article, we’ll explore what the latest research tells us about how patients use Rybelsus in everyday practice-how long they stay on it, why they stop, and most importantly, what can be done to help more people stay the course and get the full benefit of treatment.

Understanding Adherence: More Than Just Taking a Pill

In clinical research, efficacy tells us what a drug can do under ideal conditions. But in the real world, adherence determines what it actually does for most people.

When it comes to Rybelsus, adherence is more than just remembering to take a pill-it involves consistently following a very specific dosing regimen. The medication must be taken first thing in the morning on an empty stomach, with no food or drink (except water) for at least 30 minutes afterward. These rules are crucial for absorption but can make routine use more demanding than it first appears.

Let’s clarify some key terms:

  • Adherence refers to how well a patient follows the prescribed dosing instructions over time.
  • Persistence means how long a patient continues therapy without interruption.
  • Discontinuation is when the patient stops the therapy entirely, either temporarily or permanently.

Real-world studies often measure adherence using metrics like the Medication Possession Ratio (MPR) or Proportion of Days Covered (PDC)-data points that estimate how consistently patients refill and use their medication. These insights offer a window into what’s really happening after the prescription is written.

Real-World Data: How Long Do Patients Stay on Rybelsus?

While Rybelsus has shown promising efficacy in clinical trials, real-world persistence is notably more modest. Data from large U.S. claims databases such as Optum and MarketScan suggest that adherence at 6 months ranges from 45% to 55%, while 12-month persistence typically falls between 30% and 40%, depending on the population and definitions used.

For example, an Optum-based analysis (n = 1,937) found that just under half of patients were still on Rybelsus at 6 months. Twelve-month outcomes are more limited in U.S. data, but similar trends have been observed in Japanese and European cohorts.

When compared to injectable GLP-1 receptor agonists, results are mixed. In a 2024 Japanese study, 12-month persistence was 64% for oral semaglutide versus 82% for injectables. A separate meta-analysis (PubMed ID: 39680131) reported persistence of 72% for oral versus 92% for injectable GLP-1s at one year. However, some retrospective cohorts-particularly in the U.S.-showed similar or even better adherence with oral agents, likely due to patient preference and convenience.

The bottom line: oral administration alone doesn’t guarantee long-term use. Adherence depends on a combination of medication tolerability, regimen complexity, and patient expectations.

Why Patients Stop Taking Rybelsus: Common Real-World Barriers

Understanding why patients discontinue Rybelsus is key to improving long-term outcomes. Real-world data and patient interviews consistently highlight several recurring themes behind early dropout.

Gastrointestinal side effects

Nausea, vomiting, and diarrhea are the most common reasons for stopping Rybelsus-especially during the first few weeks of therapy. While these symptoms are often temporary and dose-related, many patients are not prepared for the intensity and don’t receive enough support to manage them.

Inconvenient dosing requirements

Unlike most oral medications, Rybelsus must be taken on an empty stomach with water, and patients must wait at least 30 minutes before eating or drinking anything else. This strict morning routine can feel disruptive, particularly for those with busy or irregular schedules.

Lack of immediate results

Patients often expect rapid improvements in blood sugar or weight. When changes aren’t visible within a few weeks, some become discouraged and discontinue prematurely-especially if they also experience side effects.

Cost and insurance coverage

Without adequate insurance, Rybelsus can be expensive. High copays or coverage denials frequently lead to early abandonment of therapy.

Psychosocial and behavioral factors

Low motivation, unrealistic expectations, or mental health challenges (such as depression) can all affect medication adherence. In older patients, polypharmacy and comorbidities make it harder to prioritize a drug like Rybelsus without clear perceived benefit.

Adherence can be significantly improved by identifying and addressing these barriers early, thereby supporting patient retention and therapeutic success.

Who Sticks With Rybelsus: Predictors of Better Adherence

Although adherence to Rybelsus is variable, certain patterns have emerged in real-world studies.

Analyses from claims databases, including a Prime Therapeutics-based study (PMID: 38717042), suggest that female patients, those aged 45–64 years, and individuals with commercial insurance or Medicare Advantage plans tend to have higher adherence rates. Additionally, patients with prior exposure to GLP-1 or DPP-4 therapies and those with obesity seeking weight loss often show stronger commitment to staying on treatment.

Importantly, these associations are not universal. They have been observed in specific subgroups and may not apply across all populations. Sociobehavioral context, clinical education, and patient support systems often play a greater role than demographics alone.

Understanding these tendencies, however, can help clinicians anticipate who might need more proactive support at the start of therapy.

Boosting Adherence: Three Key Areas to Focus On

Improving adherence to Rybelsus means addressing not just the medication itself, but also the patient’s experience with it. Real-world strategies fall into three main categories: education, support, and access.

Education: Set the foundation early

  • How Rybelsus works and typical timelines for effect
  • The importance of morning dosing on an empty stomach
  • Why slow dose escalation helps with tolerability

Support: Stay connected in the first 90 days

  • Regular follow-ups (in-person or remote) during titration
  • Personalized side-effect management plans
  • Digital tools such as reminders, tracking apps, or pill organizers

Access: Remove financial and administrative barriers

  • Introduce co-pay cards or discount programs early
  • Help navigate prior authorizations or formulary questions
  • Discuss affordability options during the first visit

Adherence support in these three areas can significantly increase the likelihood that patients stick with Rybelsus and achieve long-term benefits.

Why Staying on Rybelsus Matters: Adherence and Long-Term Outcomes

Staying on Rybelsus for 12 months or more isn’t just about “sticking with the plan”-it’s essential for achieving the full spectrum of clinical benefits.

Patients who remain on oral semaglutide tend to see greater and more sustained reductions in HbA1c, improved weight loss trajectories, and-perhaps most importantly-organ-level benefits that emerge over time.

In March 2025, the landmark SOUL trial confirmed that oral semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 14% (hazard ratio 0.86) in patients with type 2 diabetes and high cardiovascular risk.

As for kidney outcomes, current evidence is limited to injectable semaglutide (see FLOW trial). While it’s possible that renal protection is a class effect, this has not yet been demonstrated for the oral formulation and should be interpreted cautiously.

In short, consistent long-term adherence is what transforms Rybelsus from a glucose-lowering agent into a broader disease-modifying therapy.

Given the compelling evidence for sustained Rybelsus use, many patients understandably seek clarity on the financial commitment required for long-term therapy. The total cost of a 12-month Rybelsus course varies significantly based on dosage strength (3mg, 7mg, or 14mg tablets), insurance coverage, and pharmacy pricing, with uninsured annual costs typically ranging from $9,000 to $14,000 USD. Fortunately, strategic savings approaches exist: We’ve detailed actionable solutions in our companion article How to Save on Rybelsus, covering manufacturer coupons, pharmacy comparison tactics, and alternative access programs that can substantially reduce out-of-pocket expenses without compromising treatment continuity.

Conclusion

In clinical trials, Rybelsus has shown strong potential as an effective oral GLP-1 receptor agonist-but in real-world use, adherence is a critical variable that can limit its full potential.

Data suggest that a significant portion of patients discontinue Rybelsus within the first year, often due to gastrointestinal side effects, the strict morning dosing routine, or lack of early perceived results. Still, certain group-such as motivated patients with obesity or strong support systems-demonstrate better long-term persistence.

To truly realize the benefits of Rybelsus, support for adherence must be part of the treatment plan from day one. This includes managing expectations, providing follow-up, addressing cost barriers, and engaging patients in shared decisions.

Shared decision-making is a key component in building the foundation for sustained metabolic and organ-level outcomes. Patients, clinicians, and health systems all have a role to play in making that happen.

References

© 2025 website-pace

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.
Cookies settings
Accept
Privacy & Cookie policy
Privacy & Cookies policy
Cookies list
Cookie name Active
Save settings
Cookies settings